# KRYSTAL-12 (NCT04685135)

> Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04685135
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Mirati Therapeutics Inc.
- Conditions: Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer
- Interventions: MRTX849; Docetaxel
- Enrollment: 453
- Primary outcome: Progression-Free Survival (PFS) as Per Blinded Independent Central Review

## Commentary we found

- X threads: 96
- YouTube: 22
- Podcasts: 17
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=krystal-12-nct04685135

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04685135", "email": "<work email>"}; the inbox owner confirms by the emailed link.